Most Recent
Zoetis has been ordered to pay Scidera’s costs of defending an unsuccessful summary dismissal application on a lump sum basis in a dispute over a bovine gene patent, with a judge rejecting its “premature” bid for a set-off.
A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.
Suspecting infringement of patents for its Parkinson's drug, Xadago, biopharmaceutical company Newron has won preliminary discovery of documents from generic drug maker Arrotex Pharmaceuticals.
Animal drug company Zoetis has lost its bid for summary dismissal of claims that it infringed US-based animal genomics company Scidera's bovine gene patent, with a judge saying its novel arguments were not so clear-cut and needed to be worked out at trial.
The High Court has rejected Novartis' plea that it overturn a ruling that found an extension of the term of the patent for its heart drug Entresto was invalidly granted.
A group of Australia’s leading beef and dairy companies has failed to strike-out a suit alleging their genetic testing system for cattle infringes the patent of a US genomics company, with a judge rejecting objections to the phrase ‘further or in the alternative’.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis' appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
US animal drug manufacturer Zoetis has lost its challenge a ruling that chucked out three of its patents for a single-dose vaccine to protect pigs from enzootic pneumonia.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.